Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of non-psychoactive cannabinoid (“CBD”) and synthetic CBD medicines that address the unmet needs of large patient populations, today reported the Company has received growing media coverage in recent weeks.
In an October 8, 2015 article titled, “Medical vs. Recreational Marijuana Investing,” Marijuana Investor News (“MJIN”) states, “Right now, there are several different schools of thought within the industry and investment community on which companies make better if not lower risk investments, as well as which companies in the still-developing market are likely to go public first.”
The article goes on to say, “Seth Yakatan, CEO of Kalytera, explained, ’That will largely be mediated by regulation.’ That said, he is the first to admit that ’there are no absolutes. Ultimately good investments come down to execution. There is no way to predict what will be low risk. Medical investments have an inherent high level of risk given the failure rate of most pharmaceutical and biotech drugs at the U.S. FDA’.”
For the complete article, see: http://www.mjinews.com/will-marijuana-market-continue-go-public/.
In an October 6, 2015 article titled, “Medical vs. Recreational Marijuana Investing,” MJIN states, “In the weeds of decision-making, however, most also concur that investors have to fully educate themselves about the shape of the markets they invest in beyond company specifics or mission.”
In the article, Mr. Yacatan is quoted, “’Certainly there is no questioning the hyper growth to be experienced in the cannabis industry – both medical or recreational,’ said Seth Yakatan the CEO of Kalytera. ’Although the recreational market might show more immediate profits, and providing that you choose the right company the long term upside is much greater in the medical market over the long run.’”
For the complete article, see: http://www.mjinews.com/medical-vs-recreational-marijuana-investing/.
In a September 16, 2015 article, titled “The CBD Invasion of Europe,” MJIN reports, “Not one but several companies who manufacture and distribute cannabinoid-processed end products are looking to European expansion. The move is being driven by an opening of the British market this summer after the government allowed processed hemp, or cannabidiol, to be sold in England.”
“’Kalytera is developing a portfolio of non-psychoactive cannabinoid and cannabinoid-modulating medicines that address large unmet market needs, with an initial focus on bone healing and osteoporosis and bone healing,’ said Seth Yakatan, the CEO of Kalytera Therapeutics. ’Historically CBD has been difficult to commercialize as its structure is known and no pharmaceutical based therapeutic claims can be made for CBD. Kalytera seeks to overcome these obstacles with our propriety form of a pharmaceutical product.’”
For the complete article, see: http://www.mjinews.com/cbd-invasion-europe/.
Kalytera provides the information and links in this news release as a courtesy to its investors, partners and friends of the firm for informational purposes only. The Company neither endorses nor refutes the content contained in these articles, including Kalytera quotes or the context within which they are presented.
Kalytera Therapeutics, Inc. is a pharmaceutical company that is developing a portfolio of non-psychoactive cannabinoid and cannabinoid-modulating medicines that address the unmet needs of large patient populations. The Company seeks to commercialize its proprietary, synthetic cannabinoid therapies across a range of disease states, with an initial focus on bone healing and osteoporosis.
This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market, and the availability of funding sources for continued development of such products. Forward-looking statements are based on management’s estimates, assumptions, and projections, and are subject to uncertainties, many of which are beyond the control of Kalytera. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that potential products that appear promising to Kalytera cannot be shown to be efficacious or safe in subsequent preclinical or clinical trials, Kalytera will not obtain appropriate or necessary governmental approvals to market these or other potential products, Kalytera may not be able to obtain anticipated funding for its development projects or other needed funding, and Kalytera may not be able to secure or enforce adequate legal protection, including patent protection, for its products. All forward-looking statements included in this press release are made only as of the date of this press release, and Kalytera does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.